The Neurotech Industry Investing and Partnering Conference Highlights Innovative Companies in Commercial Neuroscience
BOSTON & SAN FRANCISO -- "Next Generation Neuropsychiatry," "Drug Delivery and the Blood Brain Barrier" and "Effective Global Clinical Trial Design" are just a few of the many cutting edge subjects to be tackled at The Neurotech Industry Investing and Partnering Conference. Hosted by NeuroInsights and the Neurotechnology Industry Organization (NIO), the third annual investor and partnering conference for drugs, devices and diagnostics for the brain and nervous system will take place May 8-9 at the Westin Copley Place in Boston.
The two-day program will offer a number of sessions covering a broad spectrum of issues from neurotech investments to new advances in treatments and therapies for a wide range of neuroscience-related indications. Scheduled session topics include:
· Addiction, Impulse Control and Obesity: Advancing science and acceptance of addiction as a brain disorder are creating opportunities for addressing unmet markets including nicotine, alcohol, and gambling. Treatments for impulse control may also apply to the massive obesity market.
· Traumatic Brain and Spinal Cord Injury: New hope is emerging for treatments of major traumatic injuries to the central nervous system. While venture funding may be scare for such challenging areas, companies are leveraging government support and innovative financing to address these unmet markets.
· Pain: Acute, Chronic, and Neuropathic: New and innovative pain treatments are reaching the market ranging from abuse resistant opiate formulations to neurofeedback to noninvasive neuro-stimulation. Leading edge drug, drug delivery and device companies are working towards treatments for neuropathic pain by targeting entirely new pathways.
·Alzheimer's and Cognitive Disorders: As the population ages, the market for Alzheimer's and other cognitive disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?
"The Neurotech Industry Investing and Partnering conference covers the full scope of neurotechnology innovation, from new and dynamic therapies to innovative investment opportunities," stated Casey Lynch, managing director of NeuroInsights. "This conference is the premier annual event for industry executives and members of the financial community to meet, network, and discuss upcoming neurotechnology trends and investment prospects."
This year's conference will feature corporate presentations from more than 40 public and private neuroscience companies, three panel sessions, plus plenary sessions on timely business issues and industry trends. The event also offers many opportunities to schedule one-on-one meetings, as well as numerous networking prospects, including a partnering lunch sponsored by NIO. The conference is designed to foster an informative dialogue between investors and senior neurotechnology executives about current and emerging opportunities.
For more information on The Neurotech Industry Investing and Partnering Conference, including registration, hotel accommodations and an up-to-date program, please visit the conference website at http://www.neuroinsights.com/events/neurotech2008.html. Advance media registration is available at http://www.neuroinsights.com/media.html.
NeuroInsights is the world's leading neurotechnology research and advisory firm. As the neurotechnology market authority, NeuroInsights helps investors, industry and society understand and profit from the rapid growth in drugs, devices and diagnostics for the brain and nervous system. NeuroInsights provides market reports, investment information, industry events and strategic advisory services to venture funds, startups, corporations, governments and financial institutions. For more information, visit www.neuroinsights.com.
The Neurotechnology Industry Organization (NIO) represents companies involved in neuroscience - drugs, devices and diagnostics, brain research centers, and advocacy groups across the world. Since NIO's founding in August 2006, over 60 organizations have joined to "give the brain a voice." More information: www.neurotechindustry.org